The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Open accessThe DOI matches its Crossref record; 452 of the 457 references it cites were found in a registry or an index.
Abstract
The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs. This hypothesis was based on the discovery that fibril-free synthetic preparations of AβOs were potent CNS neurotoxins that rapidly inhibited long-term potentiation and, with time, caused selective nerve cell death (Lambert et al., 1998). The mechanism was attributed to disrupted signaling involving the tyrosine-protein kinase Fyn, mediated by an unknown toxin receptor. Over 4,000 articles concerning AβOs have been published since then, including more than 400 reviews. AβOs have been shown to accumulate in an AD-dependent manner in human and animal model brain tissue and, experimentally, to impair learning and memory and instigate major facets of AD neuropathology, including tau pathology, synapse deterioration and loss, inflammation, and oxidative damage. As reviewed by Hayden and Teplow in 2013, the AβO hypothesis "has all but supplanted the amyloid cascade." Despite the emerging understanding of the role played by AβOs in AD pathogenesis, AβOs have not yet received the clinical attention given to amyloid plaques, which have been at the core of major attempts at therapeutics and diagnostics but are no longer regarded as the most pathogenic form of Aβ. However, if the momentum of AβO research continues, particularly efforts to elucidate key aspects of structure, a clear path to a successful disease modifying therapy can be envisioned. Ensuring that lessons learned from recent, late-stage clinical failures are applied appropriately throughout therapeutic development will further enable the likelihood of a successful therapy in the near-term.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig.1 AβOs, not Aβ monomers or fibrils, instigate the neuron damage leading to dementia. Following cleavage from the membrane, Aβ peptides aggregate to form AβOs, some of which further aggregate to fibrils and some of which instigate the neuron damage leading to dementia. Reprinted with Jannis Productions permissions from the “Progress Report on Alzheimer’s Disease 2004-2005” (ed. AB Rodgers), NIH Publication Number: 05-5724. Digital images produced by Stacy Jannis and Rebekah Fredenburg of Jannis Productions [455].](https://figures.cochat.ai/paper-figures/f6b42a17775e4881b942c99d83b0c0fa/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-1.jpg)
![Fig.2 AβOs instigate multiple facets of AD-neuropathology. Observed in various culture and animal models. Reprinted by permission from Springer Nature: Acta Neuropathol, 129(2): 183-206, “Amyloid beta oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis” by Viola KL and Klein WL. Copyright 2015 Springer Nature [200].](https://figures.cochat.ai/paper-figures/4c12da5f31934b84a9263cc86d9b1ffd/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-2.jpg)

![Fig.4 AβOs can be divided into two classes based on their temporal, spatial, and structural relationships to amyloid plaques as well as their ability to cause memory dysfunction. Type 1 AβOs (aka “peak 1” or HMW) are thought to be associated with memory impairment, while type 2 AβOs (aka “peak 2” or LMW) are not. Only type 2 AβOs are associated with amyloid plaques. Reprinted from “Quaternary Structure Defines a Large Class of Amyloid-beta Oligomers Neutralized by Sequestration” by Liu P, Reed MN, Kotilinek LA, Grant MK, Forster CL, Qiang W, Shapiro SL, Reichl JH, Chiang AC, Jankowsky JL, Wilmot CM, Cleary JP, Zahs KR, and Ashe KH. This was published in Cell Rep, 2015, 11(11): 1760-1771, under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/ [119].](https://figures.cochat.ai/paper-figures/c5448ccd6aa14c24a04007d7a6986c4e/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-4.jpg)
![Fig.5 Only high-molecular weight AβOs are capable of binding cultured hippocampal neurons. Synthetic AβOs were divided into high and low molecular weight populations using 50 kDa molecular weight cutoff ultrafiltration (A-B) or size exclusion chromatography (D-F) and incubated with cultured hippocampal neurons. Only high-molecular weight AβOs bind neurons (A, E); no binding of low-molecular weight AβOs was evident (B, F). Scale bar = 40μm. Reprinted from “Synaptic targeting by Alzheimer’s-related amyloid beta oligomers” by Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, and Klein WL. This was published in J Neurosci, 2004, 24(45): 10191-10200, copyright 2004; permission conveyed through Copyright Clearance Center, Inc. [16].](https://figures.cochat.ai/paper-figures/16de889766c74140a8a5dc196a8cc4d2/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-5.jpg)
![Fig.6 PrPc mediates AβO toxicity through mGluR5, Fyn kinase, and NMDARs. Downstream consequences of the pathway include calcium dyshomeostasis, tau hyperphosphorylation, and synaptic dysfunction and loss. Reprinted from “Fyn kinase inhibition as a novel therapy for Alzheimer’s disease” by Nygaard HB, van Dyck CH, and Strittmater SM. This was published in Alzheimers Res Ther, 2014, 6(1): 8, under the terms of the Creative Commons Attribution License (CC BY) [227].](https://figures.cochat.ai/paper-figures/f727ef34b3b345d8b849289bdb182350/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-6.jpg)
![Fig.7 AβOs induce membrane re-distribution of NKAα3 subunit resulting its downregulation and excessive Ca++ buildup. A hypothesized early event in AβO-induced neuronal damage is binding to NKAα3 on neuronal membranes, causing restructuring of the NKAα3 docking station into toxic clusters of membrane proteins. Ultimately, this results in downregulation of NKAα3 on the neuronal surface and buildup of toxic Ca++. Adapted and reprinted from “Alzheimer’s Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station” by DiChiara T, DiNunno N, Clark J, Bu RL, Cline EN, Rollins MG, Gong Y, Brody DL, Sligar SG, Velasco PT, Viola KL, and Klein WL. This was published in Yale J Biol Med, 2017, 90(1): 45-61, under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/ [199].](https://figures.cochat.ai/paper-figures/bd05d1a512054c909e16e461e4020c7c/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-7.jpg)
![Fig.8 A cumulative hypothesis for the development of sporadic AD. From De Felice, sporadic AD is hypothesized to be the result of the cumulative impact over a life-time of injuries to the brain and peripheral organs that results in increased AβO levels. Reprinted from “Alzheimer’s disease and insulin resistance: translating basic science into clinical applications” by De Felice FG. This was published in JClin Invest, 2013, 123(2): 531-539, under Free access [322].](https://figures.cochat.ai/paper-figures/24020b5bf03e43718e18004cdfcd4325/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-8.jpg)
![Fig.9 Putative therapeutic targets of the AβO pathogenic cascade. Including: 1) AβOs themselves; 2) AβO receptors; 3) signaling pathways; or 4) downstream effectors such as tau. Reprinted with permission of PNAS from “Toward a unified therapeutics approach targeting putative amyloid-beta oligomer receptors” by Overk CR and Masliah E. This was published in Proc Natl Acad Sci U S A, 2014, 111(38): 13680-13681 [392].](https://figures.cochat.ai/paper-figures/fd1348f91c8947ff93496ee3a5d93873/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-9.jpg)
![Fig.10 Mechanisms of Aβ-targeting phase III drugs in AD clinical trials. Drugs inhibiting AβO formation (A) or downstream consequences of toxic AβOs (B). Reprinted from “Alzheimer’s disease drug development pipeline: 2017” by Cummings J, Garam L, Mortsdorf T, Ritter A, and Zhong K. This was published in Alzheimers Dementia (N Y), 2017, 3(3): 367-384 [393], under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY NC ND) https://creativecommons.org/licenses/by-nc-nd/4.0/) [393].](https://figures.cochat.ai/paper-figures/3fe1a59ed5324adab364ba96901a832d/the-amyloid-oligomer-hypothesis-beginning-of-the-third-decade-figure-10.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Soluble Aβ oligomers are the primary neurotoxic substances,131–133”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [131]
The cited source says what the claim attributes to it.
In the citing paper
“Misfolded Aβ and tau proteins accumulate in the AD brain in a neurodegenerative cascade leading to cognitive decline and dementia [4,5,6,7,8,9].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“The Aβ oligomer hypothesis, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers rather than amyloid plaques as key players in AD pathogenesis [4,5,6,7].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Elevated levels of oligomers have been associated with AD, as they are found in AD brains and are considered the most toxic and pathogenic form of Aβ [4,5,6,7,18].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [6]
In the citing paper
“The alternative “Aβ oligomer hypothesis”, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers (AβO)s rather than amyloid plaques as key players in AD pathogenesis [79,80,81].”
From Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery (2021) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedLarson, M., Sherman, M. A., Amar, F., Nuvolone, M., Schneider, J. A., Bennett, D. A., Aguzzi, A., & Lesné, S. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1858-12.2012 · Cited by 277
RetractedRETRACTED: Cognitive effects of cell-derived and synthetically derived Aβ oligomers
Reed, M. N., Hofmeister, J. J., Jungbauer, L. M., Welzel, A. T., Yu, C., Sherman, M. A., Lesné, S., LaDu, M. J., Walsh, D. M., Ashe, K. H., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.11.007 · Cited by 136
RetractedAmar, F., Sherman, M. A., Rush, T., Larson, M. E., Boyle, G. E., Liu, C., Götz, J., Buisson, A., & Lesné, S. (2017) · Science Signaling · doi:10.1126/scisignal.aal2021 · Cited by 118
RetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Research works printed but not linked: 4
- Meilandt, 2017, Characterization of the selective in vivo and in vitro binding properties of crenezumab: Insights into crenezumab’s unique mechanism of action, J Prev Alzheimers Dis, 4, 293
- Schneider, 2017, The anti-AB oligomer drug CT1812 for Alzheimer’s: Phase 1B/2A safety trial outcomes, J Prev Alzheimers Dis, 4, 317
- Catalano, 2017, Biomarker outcomes from the phase 1b/2a safety trial of the anti-AB oligomer drug CT1812 in Alzheimer’s patients, J Prev Alzheimers Dis, 4, 401
- Leslie, 2017, Phase II study to assess safety and target engagement of AMX0035, a novel combination therapy, in Alzheimer’s disease, Neurotherapeutics, 14, 825
Cited by
Items 201–300 of 867
Singh, Y. P., Kumar, N., Priya, K., Chauhan, B. S., Shankar, G., Kumar, S., Singh, G. K., Srikrishna, S., Garg, P., Singh, G., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00443 · Cited by 32
Bazrgar, M., Khodabakhsh, P., Dargahi, L., Mohagheghi, F., & Ahmadiani, A. (2022) · Experimental Gerontology · doi:10.1016/j.exger.2022.111812 · Cited by 32
Song, C., Zhang, T., & Zhang, Y. (2022) · Molecules · doi:10.3390/molecules27196751 · Cited by 34
Scala, C. D., Armstrong, N., Chahinian, H., Chabrière, É., Fantini, J., & Yahi, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113383 · Cited by 34
Gonçalves, R. G. D. J., Vasques, J. F., da Silva‐Junior, A. J., Gubert, F., & Méndez‐Otero, R. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.361546 · Cited by 36
A metabolic perspective of late onset Alzheimer’s disease
Ettcheto, M., Cano, A. C., Busquets, O., Manzine, P. R., Sánchez‐López, E., Castro-Torres, R. D., Beas‐Zárate, C., Verdaguer, E., García, M. L., Olloquequi, J., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104255 · Cited by 34
Yu, L., Petyuk, V., Tasaki, S., Boyle, P. A., Gaiteri, C., Schneider, J. A., Jager, P. L. D., & Bennett, D. A. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0834 · Cited by 32
Post-Translational Modifications of BACE1 in Alzheimer's Disease
Wen, W., Li, P., Liu, P., Xu, S., Wang, F., & Huang, J. H. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210121163224 · Cited by 36
Watanabe‐Nakayama, T., Tsuji, M., Umeda, K., Oguchi, T., Konno, H., Noguchi‐Shinohara, M., Kiuchi, Y., Kodera, N., Teplow, D. B., & Ono, K. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c00187 · Cited by 32
Kommaddi, R. P., Gowaikar, R., Haseena, P. A., Diwakar, L., Singh, K. P., & Mondal, A. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105619 · Cited by 30
Asiatic acid and its derivatives: Pharmacological insights and applications
Liang, C., Ma, Y., Ding, M., Gao, F., Yu, K., Wang, S., Qu, Y., Hu, X., & Li, D. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117429 · Cited by 33
Exploring the Role of P2X Receptors in Alzheimer’s Disease
Godoy, P. A., Ramírez-Molina, O., & Fuentealba, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01330 · Cited by 31
Zhang, J., Chen, B., Lu, J., Wu, Y., Wang, S., Yao, Z., Zhu, L., Qiao, Y., Sun, Q., Qin, W., et al. (2019) · Aging Cell · doi:10.1111/acel.12978 · Cited by 35
Compartmentalized Signaling in Aging and Neurodegeneration
di Benedetto, G., Iannucci, L. F., Surdo, N. C., Zanin, S., Conca, F., Grisan, F., Gerbino, A., & Lefkimmiatis, K. (2021) · Cells · doi:10.3390/cells10020464 · Cited by 28
Viola, K. L., Bicca, M. A., Bebenek, A. M., Kranz, D. L., Nandwana, V., Waters, E. A., Haney, C. R., Lee, M. Y., Gupta, A., Brahmbhatt, Z., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.768646 · Cited by 32
Self-citationHettmann, T., Gillies, S. D., Kleinschmidt, M., Piechotta, A., Makioka, K., Lemere, C. A., Schilling, S., Rahfeld, J., & Lues, I. (2020) · Scientific Reports · doi:10.1038/s41598-020-60319-5 · Cited by 29
Membrane channel hypothesis of lysosomal permeabilization by beta-amyloid
Zaretsky, D. V., Zaretskaia, M. V., & Molkov, Y. I. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136338 · Cited by 28
Billard, J. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00106 · Cited by 31
Xiao, Y., Matsuda, I., Inoue, M., Sasahara, T., Hoshi, M. M., & Ishii, Y. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.008522 · Cited by 30
Özdemir, A. Y., Hofbauerová, K., Kopecký, V., Novotný, J., & Rudajev, V. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00657-8 · Cited by 27
Vishnumukkala, T., Nassir, C. M. N. C. M., Hein, Z. M., Gopalakrishna, P. K., Karikalan, B., Alkatiri, A., Jagadeesan, S., Naik, V. R., Thomas, W., Moklas, M. A. M., et al. (2025) · Cells · doi:10.3390/cells14191497 · Cited by 32
Zhou, Y., Lü, X., Yang, H., Chen, Y., Wang, F., Li, J., Tang, Z., Cheng, X.-F., Yang, Y., Xu, L., et al. (2019) · Molecules · doi:10.3390/molecules24234217 · Cited by 27
Mini-review: amyloid degradation toxicity hypothesis of Alzheimer's disease
Zaretsky, D. V., & Zaretskaia, M. V. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.135959 · Cited by 28
Microglia show differential transcriptomic response to Aβ peptide aggregates ex vivo and in vivo
McFarland, K. N., Ceballos, C., Rosario, A. M., Ladd, T. B., Moore, B. D., Golde, G., Wang, X., Allen, M., Ertekin‐Taner, N., Funk, C. C., et al. (2021) · Life Science Alliance · doi:10.26508/lsa.202101108 · Cited by 35
The Impact of Ageing on the CNS Immune Response in Alzheimer’s Disease
Chee, S. E. J., & Solito, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.738511 · Cited by 29
Pedersen, K. B., Flores‐Canales, J. C., & Schiøtt, B. (2022) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26409 · Cited by 28
Bhopatkar, A. A., & Kayed, R. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105122 · Cited by 30
Polymer–Metal Composite Healthcare Materials: From Nano to Device Scale
Wong, W., Lai, C.-H. N., Cheng, W., Tung, L.-H., Chang, R. C., & Leung, F. K. (2022) · Journal of Composites Science · doi:10.3390/jcs6080218 · Cited by 26
Natural products targeting amyloid-β oligomer neurotoxicity in Alzheimer's disease
Gonçalves, P. B., Sodero, A. C. R., & Cordeiro, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116684 · Cited by 27
Alzheimer’s protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity
Limegrover, C. S., LeVine, H., Izzo, N. J., Yurko, R., Mozzoni, K., Rehak, C., Sadlek, K., Safferstein, H., & Catalano, S. M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15212 · Cited by 24
Murti, B. T., Putri, A. D., Huang, Y., Wei, S.-M., Peng, C., & Yang, P. (2021) · RSC Advances · doi:10.1039/d1ra01553b · Cited by 32
Ruver-Martins, A. C., Bicca, M. A., de Araujo, F. S., Maia, B. H. L. D. N. S., Pamplona, F. A., da Silva, É. G., & do Nascimento, F. P. (2022) · Journal of Medical Case Reports · doi:10.1186/s13256-022-03457-w · Cited by 27
Self-citationSingh, K., Kaur, A., Goyal, D., & Goyal, B. (2022) · Physical Chemistry Chemical Physics · doi:10.1039/d2cp02601e · Cited by 26
Phosphorylation at Ser289 Enhances the Oligomerization of Tau Repeat R2
Man, V. H., He, X., Han, F., Cai, L., Wang, L., Niu, T., Zhai, J., Ji, B., Gao, J., & Wang, J. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01597 · Cited by 30
The Brain’s Glymphatic System: Drawing New Perspectives in Neuroscience
Ciurea, A. V., Mohan, A. G., Covache-Busuioc, R.-A., Costin, H. P., & Saceleanu, V. M. (2023) · Brain Sciences · doi:10.3390/brainsci13071005 · Cited by 31
Cisternas, P., Zolezzi, J. M., Lindsay, C. B., Rivera, D. S., Martinez, A. N., Bozinovic, F., & Inestrosa, N. C. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180729 · Cited by 29
Molecular Mechanism and Kinetics of Amyloid-β42 Aggregate Formation: A Simulation Study
Man, V. H., He, X., Ji, B., Liu, S., Xie, X., & Wang, J. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00473 · Cited by 28
Mitroshina, Е. V., Yarkov, R. S., Mishchenko, T. A., Krut’, V. G., Gavrish, M. S., Epifanova, E. A., Babaev, A. A., & Vedunova, M. V. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00582 · Cited by 31
Alzheimer’s Disease Immunotherapy: Current Strategies and Future Prospects
Aljassabi, A., Zieneldien, T., Kim, J., Regmi, D., & Cao, C. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231163 · Cited by 31
Neuroprotective expression of turmeric and curcumin
Abbas, S., Latif, M. S., Shafie, N. S., Ghazali, M. I., & Kormin, F. B. (2020) · Food Research · doi:10.26656/fr.2017.4(6).363 · Cited by 32
Pharmacological Strategies to Improve Dendritic Spines in Alzheimer’s Disease
Ettcheto, M., Busquets, O., Cano, A. C., Sánchez‐López, E., Manzine, P. R., Espinosa-Jiménez, T., Verdaguer, E., Sureda, F. X., Olloquequi, J., Castro-Torres, R. D., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201106 · Cited by 28
Confettura, A. D., Cuboni, E., Ammar, M. R., Jia, S., Gomes, G. M., Yuanxiang, P., Raman, R., Li, T., Grochowska, K. M., Ahrends, R., et al. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-021-00277-8 · Cited by 25
Advances in the roles and mechanisms of lignans against Alzheimer’s disease
Han, N., Wen, Y., Liu, Z., Zhai, J., Li, S., & Yin, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.960112 · Cited by 26
Cline, E. N., Das, A., Bicca, M. A., Mohammad, S. N., Schachner, L. F., Kamel, J. M., DiNunno, N., Weng, A., Paschall, J. D., Bu, R. L., et al. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14647 · Cited by 30
Self-citationAmyloid Beta Hypothesis in Alzheimer's Disease: Major Culprits and Recent Therapeutic Strategies
Dileep, K. V., & Chandra, R. (2019) · Current Drug Targets · doi:10.2174/1389450120666190806153206 · Cited by 27
Alzheimer’s Disease: A short introduction to the calmodulin hypothesis
O’Day, D. H. (2019) · AIMS neuroscience · doi:10.3934/neuroscience.2019.4.231 · Cited by 26
Therapeutic Strategies Targeting Amyloid-β Receptors and Transporters in Alzheimer’s Disease
Lao, K., Zhang, R., Luan, J., Zhang, Y., & Gou, X. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200851 · Cited by 29
Tatulian, S. A. (2024) · Physical Chemistry Chemical Physics · doi:10.1039/d4cp01136h · Cited by 25
The Gut Microbiome and Its Impact on Mood and Decision-Making: A Mechanistic and Therapeutic Review
Diotaiuti, P., Misiti, F., Marotta, G., Falese, L., Calabrò, G. E., & Mancone, S. (2025) · Nutrients · doi:10.3390/nu17213350 · Cited by 27
Phosphorylated Aβ peptides in human Down syndrome brain and different Alzheimer’s-like mouse models
Kumar, S., Lemere, C. A., & Walter, J. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00959-w · Cited by 26
Plasma Amyloid-β Oligomerization Tendency Predicts Amyloid PET Positivity
Pyun, J., Ryu, J. S., Lee, R. Y., Shim, K., Youn, Y. C., Ryoo, N., Han, S., Park, Y. H., Kang, S., An, S. S. A., et al. (2021) · Clinical Interventions in Aging · doi:10.2147/cia.s312473 · Cited by 27
Effects of the Toxic Metals Arsenite and Cadmium on α-Synuclein Aggregation In Vitro and in Cells
Lorentzon, E., Horváth, I., Kumar, R., Rodrigues, J. I., Tamás, M. J., & Wittung-Stafshede, P. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111455 · Cited by 24
Guo, C., Wen, D., Zhang, Y. H., Mustaklem, R., Mustaklem, B., Zhou, M., Ma, T., & Ma, Y. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01459-0 · Cited by 24
Halder, T., Patel, B., & Acharya, N. S. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120479 · Cited by 25
Budvytytė, R., & Valinčius, G. (2023) · Biochemical Society Transactions · doi:10.1042/bst20220434 · Cited by 25
Kumi, R. O., Soremekun, O. S., Issahaku, A. R., Agoni, C., Olotu, F. A., & Soliman, M. E. S. (2020) · Journal of Molecular Modeling · doi:10.1007/s00894-020-4319-6 · Cited by 26
The Role of Human Herpesvirus 6 Infection in Alzheimer’s Disease Pathogenicity—A Theoretical Mosaic
Romanescu, C., Schreiner, T. G., & Mukovozov, I. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11113061 · Cited by 24
“Some of the key phenomena involved include the misfolding of amyloid beta (Aβ) [10] and Tau proteins [11], chronic neuroinflammation [12], and oxidative stress [13].”
BackgroundOchiishi, T., Kaku, M., Kajsongkram, T., & Thisayakorn, K. (2021) · Genes to Cells · doi:10.1111/gtc.12889 · Cited by 29
Site specific NMR characterization of abeta-40 oligomers cross seeded by abeta-42 oligomers
Chang, H., Ma, H.-I., Wu, Y., Lee, M., Yuan, E. C., Huang, S., Cheng, Y.-S., Wu, M., Tu, L., & Chan, J. C. C. (2022) · Chemical Science · doi:10.1039/d2sc01555b · Cited by 23
Yu, Z., Guo, W., Patel, S., Cho, H., Sun, L., & Mirica, L. M. (2022) · Chemical Science · doi:10.1039/d2sc02654f · Cited by 28
Targeting soluble amyloid-beta oligomers with a novel nanobody
Haynes, J. R., Whitmore, C. A., Behof, W. J., Landman, C. A., Ong, H. H., Feld, A. P., Suero, I. C., Greer, C. B., Gore, J. C., Wijesinghe, P., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-66970-6 · Cited by 27
Woods, J. J., Skelding, K. A., Martin, K. L., Aryal, R., Sontag, E., Johnstone, D. M., Horvat, J. C., Hansbro, P. M., & Milward, E. A. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.10.014 · Cited by 25
A single-domain antibody detects and neutralises toxic Aβ42 oligomers in the Alzheimer’s disease CSF
Bigi, A., Napolitano, L., Vadukul, D. M., Chiti, F., Cecchi, C., Aprile, F. A., & Cascella, R. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01361-z · Cited by 26
Patricio-Martínez, A., Patricio, F., Macuil-Chapuli, E., Martínez-Juárez, E. Á., Flores-Díaz, S., Cedillo-Ramirez, M. L., & Limón, I. D. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1598011 · Cited by 28
Calcium-Involved Action of Phytochemicals: Carotenoids and Monoterpenes in the Brain
Rzajew, J., Radzik, T., & Rębas, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041428 · Cited by 27
Kaur, A., Goyal, D., & Goyal, B. (2020) · Physical Chemistry Chemical Physics · doi:10.1039/d0cp04672h · Cited by 22
Chowdhury, S. R., Gu, J., Hu, Y., Wang, J., Lei, S., Tavallaie, M. S., Lam, C., Lü, D., Jiang, F., & Fu, L. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113541 · Cited by 23
Valencia-Olvera, A. C., Balu, D., Faulk, N., Amiridis, A., Wang, Y., Pham, C., Avila-Munoz, E., York, J. M., Thatcher, G. R. J., & LaDu, M. J. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01375-3 · Cited by 22
Endocytic pathways of pathogenic protein aggregates in neurodegenerative diseases
Hivare, P., Mujmer, K., Swarup, G., Gupta, S. K., & Bhatia, D. D. (2023) · Traffic · doi:10.1111/tra.12906 · Cited by 26
O’Day, D. H. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45080393 · Cited by 23
Serotonin Receptors as a Potential Target in the Treatment of Alzheimer’s Disease
Eremin, D. V., Kondaurova, E. M., Rodnyy, A. Y., Molobekova, C. A., Kudlay, D. A., & Naumenko, V. S. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923120064 · Cited by 25
Acute and chronic excitotoxicity in ischemic stroke and late-onset Alzheimer’s disease
Yu, S. P., Choi, E., Jiang, M. Q., & Wei, L. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00398 · Cited by 27
Serotonergic Regulation in Alzheimer’s Disease
Долгачева, Л. П., Зинченко, В. П., Nadeev, A. D., & Goncharov, N. V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115218 · Cited by 25
Amyloid pathology and synaptic loss in pathological aging
Gkanatsiou, E., Nilsson, J., Toomey, C. E., Vrillon, A., Kvartsberg, H., Portelius, E., Zetterberg, H., Blennow, K., Brinkmalm, A., Lashley, T., et al. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15487 · Cited by 24
Alzheimer’s disease is an inherent, natural part of human brain aging: an integrated perspective
Ferrer, I. (2022) · Free Neuropathology · doi:10.17879/freeneuropathology-2022-3806 · Cited by 30
O’Day, D. H. (2024) · Biomolecules · doi:10.3390/biom14020173 · Cited by 22
Umeda, T., Hatanaka, Y., Sakai, A., & Tomiyama, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168453 · Cited by 23
Confer, M. P., Holcombe, B., Foes, A., Holmquist, J. M., Walker, S. C., Deb, S., & Ghosh, A. (2021) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.1c02306 · Cited by 21
Impact of New Drugs for Therapeutic Intervention in Alzheimer’s Disease
Olloquequi, J., Ettcheto, M., Cano, A. C., Sánchez‐López, E., Carrasco, M., Espinosa-Jiménez, T., Beas‐Zárate, C., Gudiño‐Cabrera, G., Ureña‐Guerrero, M. E., Verdaguer, E., et al. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2705146 · Cited by 27
Amyloid-β oligomers, curvilinear and annular assemblies, imaged by cryo-ET, cryo-EM, and AFM
Liang, R., Khursheed, A., Tahirbegi, I. B., Torres‐Flores, A. P., Qi, S., Tian, Y., Zhang, H., Szwedziak, P., Volkov, V. A., Darbari, V. C., et al. (2025) · Science Advances · doi:10.1126/sciadv.adx9030 · Cited by 26
A randomized clinical trial of low-dose cannabis extract in Alzheimer's disease
Cury, R. D. M., da Silva, T., Cezar‐dos‐Santos, F., Fakih, Y. R. C., Narvaez, K. A. R., Gouvea, M. C., Espínola, C., Ferreira, C. F., de Castro, W. A. C., Pamplona, F. A., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251389608 · Cited by 25
Self-citationHu, B., Geng, C., Guo, F., Liu, Y., Zong, Y.-C., & Hou, X. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.08.003 · Cited by 21
Copper chelating cyclic peptidomimetic inhibits Aβ fibrillogenesis
Kalita, S., Kalita, S., Kawa, A. H., Shill, S., Gupta, A., Kumar, S., & Mandal, B. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00019a · Cited by 21
Bonomi, C. G., Assogna, M., Donna, M. G. D., Bernocchi, F., Lucia, V. D., Nuccetelli, M., Fiorelli, D., Loizzo, S., Mercuri, N. B., Koch, G., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221010 · Cited by 23
Qiu, W., Liu, H., Liu, Y., Lü, X., Wang, L., Hu, Y., Feng, F., Li, Q., & Sun, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21947 · Cited by 20
Apolipoprotein E impairs amyloid‐β fibril elongation and maturation
Islam, T., Gharibyan, A. L., Surano, S., Pettersson, N., Brännström, K., Hedberg, I., Virta, M., Olofsson, L., & Olofsson, A. (2019) · FEBS Journal · doi:10.1111/febs.15075 · Cited by 21
Enhancing α-secretase Processing for Alzheimer’s Disease—A View on SFRP1
Tang, B. L. (2020) · Brain Sciences · doi:10.3390/brainsci10020122 · Cited by 23
Membrane interaction to intercellular spread of pathology in Alzheimer’s disease
Valappil, D. K., Mini, N. J., Dilna, A., & Nath, S. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.936897 · Cited by 19
“Pore/ion channel formation (Cline et al., 2018) and lipid extraction (Arispe et al.”
BackgroundAkasaka, T., Watanabe, H., & Ono, M. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.136132 · Cited by 19
Microbiota-Gut-Brain Axis in Age-Related Neurodegenerative Diseases
Nie, T., Li, Y., Tang, F., Duan, Y., Nepovimová, E., Kuča, K., Wu, Q., & Wei, W. (2024) · Current Neuropharmacology · doi:10.2174/1570159x23666241101093436 · Cited by 24
Saieva, S., & Taglialatela, G. (2022) · Scientific Reports · doi:10.1038/s41598-022-14812-8 · Cited by 20
Arendash, G. W., Abulaban, H., Steen, S., Andel, R., Wang, Y., Bai, Y., Baranowski, R., McGarity, J., Scritsmier, L., Lin, X., et al. (2022) · Medicines · doi:10.3390/medicines9080042 · Cited by 21
The Immune System as a Therapeutic Target for Alzheimer’s Disease
Zieneldien, T., Kim, J., Sawmiller, D. R., & Cao, C. (2022) · Life · doi:10.3390/life12091440 · Cited by 24
Noninvasive Treatment of Alzheimer's Disease with Scintillating Nanotubes
Senapati, S., Secchi, V., Cova, F., Richman, M., Villa, I., Yehuda, R., Shenberger, Y., Campione, M., Rahimipour, S., & Monguzzi, A. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301527 · Cited by 20
The supersaturation perspective on the amyloid hypothesis
Barron, D. P., & Guo, Z. (2023) · Chemical Science · doi:10.1039/d3sc03981a · Cited by 19
Endocytosis Is a Key Mode of Interaction between Extracellular β-Amyloid and the Cell Membrane
Shi, J., Zhu, L., Lan, X., Zhao, D.-W., He, Y., Sun, Z.-Q., Wu, D., & Li, H. (2020) · Biophysical Journal · doi:10.1016/j.bpj.2020.07.035 · Cited by 21
Kageyama, Y., Irie, Y., Matsushima, Y., Segawa, T., Bellier, J., Hidaka, K., Sugiyama, H., Kaneda, D., Hashizume, Y., Akatsu, H., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00416 · Cited by 19
Battari, A. E., Rodriguez, L., Chahinian, H., Delézay, O., Fantini, J., Yahi, N., & Scala, C. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111550 · Cited by 21
PrPC as a Transducer of Physiological and Pathological Signals
Panes-Fernández, J., Saavedra, P., Pineda, B., Escobar, K., Cuevas, M. E., Moraga‐Cid, G., Fuentealba, J., Rivas, C. I., Rezaei, H., & Muñoz-Montesino, C. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.762918 · Cited by 21
Xue, C., Tran, J., Wang, H., Park, G., Hsu, F., & Guo, Z. (2019) · Royal Society Open Science · doi:10.1098/rsos.190179 · Cited by 21
Metadata
- Authors
- Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L.
- Affiliations
- Northwestern University (US)
- Department of Neurobiology, Cognitive Neurology and Alzheimer’s Disease Center, International Institute for Nanotechnology, and Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, USA
- Corresponding author
- Klein, William L.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2018-06-12
- Volume
- 64
- Issue
- s1
- Pages
- S567-S610
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC6004937
- OpenAlex
- W2809078375
- Cited by
- 870
- References
- 457
- Citations by year
- 2026: 72 · 2025: 109 · 2024: 99 · 2023: 133 · 2022: 123 · 2021: 123 · 2020: 119 · 2019: 74 · 2018: 17
- FWCI
- 10.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (R41AG054337, T32AG020506)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta oligomers, Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Humans, Models, Neurological, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.